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ABSTRACT 
Cancer associated fibroblasts (CAF) are abundant in the stroma of desmoplastic 
cancers where they promote tumor progression. CAF are 'activated' and as such may be 
uniquely susceptible to apoptosis. Using cholangiocarcinoma (CCA) as a desmoplastic 
tumor model, we investigated the sensitivity of liver CAF to the cytotoxic drug 
navitoclax, a BH3 mimetic. Navitoclax induced apoptosis in CAF and in myofibroblastic 
human hepatic stellate cells, but lacked similar effects in quiescent fibroblasts or CCA 
cells. Unlike CCA cells, niether CAF nor quiescent fibroblasts expressed Mcl-1, a known 
resistance factor for navitoclax cytotoxicity. Explaining this paradox, we found that 
mitochondria isolated from CAF or cells treated with navitoclax both released the 
apoptogenic factors Smac and cytochrome c, suggesting that they are primed for cell 
death. Such death priming in CAF appeared to be due in part to upregulation of the pro-
apoptotic protein Bax. shRNA-mediated attenuation of Bax 
repressed navitoclax-mediated mitochondrial dysfunction, release of apoptogenic factors 
and apoptotic cell death. In a syngeneic rat model of CCA, navitoclax treatment triggered 
CAF apoptosis, diminishing expression of the desmoplastic extracellular matrix protein 
tenascin C, suppressing tumor outgrowth and improving host survival. Together, our 
findings argue that navitoclax may be useful for destroying CAF in the tumor 
microenvironment as a general strategy to attack solid tumors. 
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INTRODUCTION   
Cancer progression is a complex, multifaceted process that involves not only 
intrinsic genetic changes unique to the malignant cell but also dynamic reciprocal 
communication between the cancer cell and stromal cells within the tumor 
microenvironment (1). As cancers progress, the stromal cells become reactive, 
phenotypically mimicking tissues undergoing wound healing or chronic inflammation.  
Indeed, many solid human cancers are characterized by desmoplasia, with high numbers 
of myofibroblasts (2).  These myofibroblasts often termed cancer associated fibroblasts 
(CAF), express tenascin C (Ten C), periostin, seprase, matrix metalloproteinases and 
other proteins promoting tumor procession, invasion and metastases (3-5).  Notably, Ten 
C has been implicated in tumor progression by facilitating metastasis (6). 
In liver, CAF likely originate from hepatic stellate cells, although CAF may also 
be derived from portal fibroblasts or potentially even from bone-marrow derived 
precursor cells (3).  Activation of hepatic stellate cells not only converts these cells into 
matrix producing myofibroblasts, but also enhances their susceptibility to apoptosis 
analogous to the activation-induced cell death observed in T-lymphocytes (7). For 
example, resolution of the wound healing response in acute liver injury is associated with 
enhanced myofibroblast apoptosis, thereby reducing their absolute numbers in the liver 
(8). By analogy, one may predict that CAF may also be uniquely sensitive to pro-
apoptotic stimuli, suggesting that selective deletion of CAF with pro-apoptotic therapies 
could potentially abrogate their support of cancer cells. This in turn, would be expected to 
negatively affect tumor survival, growth and progression. However, selectively targeting 
CAF as anticancer strategy remains largely unexplored.  
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Apoptosis is regulated by members of the Bcl-2 family of proteins, which control 
mitochondrial outer membrane permeabilization (MOMP) (9).  A pro-apoptotic subset of 
these proteins displays only a single Bcl-2 homology domain termed the BH3 domain.  
BH3-only proteins act as initiators of cell death by either promoting activation of the 
multi-domain pro-apoptotic Bcl-2 proteins Bax and Bak, (10) or by neutralizing the anti-
apoptotic Bcl-2 proteins (9). Given the ability of the BH3-only proteins to initiate cell 
death pathways, the pharmaceutical industry has developed BH3-only protein mimetics 
such as navitoclax (ABT- 263) (11).  This small organic molecule may exert single-agent 
activity in selected cells despite its inability to directly activate Bax or Bak. The direct 
cytotoxicity by a sensitizing BH3 mimetic can be explained if the mitochondria of these 
cells are “primed” for cell death (12).  In one model of priming, the mitochondrial anti-
apoptotic proteins are nearly saturated with activator BH3-only proteins. In this model, 
the BH3 mimetic may displace and liberate preexisting bound activators, thus allowing 
them to trigger Bax or Bak oligomerization and MOMP.  In an alternative model termed 
the “embedded together” model, anti-apoptotic proteins inhibit not only BH-3 only 
proteins, but also Bax or Bak within the outer mitochondrial membrane (13, 14). In this 
latter model, BH3 mimetics may alter the competing equilibrium between the various 
Bcl-2 binding partners permitting Bax or Bak activation and MOMP.   
Herein, we used cholangiocarcinoma as a model of a highly desmoplastic cancer 
to examine the role of pro-apoptotic signaling in targeting CAF. Our results suggest that 
compared to quiescent fibroblasts and CCA cells, CAF are significantly more susceptible 
to cell death by navitoclax in vitro and in vivo. Moreover, our data indicate that 
mitochondria from CAF appear to be primed for cell death. These mechanistic insights 
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expand the role of pro-apoptotic therapies in cancer by suggesting they may target the 
tumor microenvironment as well as the cancer cells.  
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MATERIALS AND METHODS 
Cell lines and culture. The human cholangiocarcinoma cell lines HuCCT-1 (15), 
Mz-ChA-1 (16), KMCH (17) and KMBC (18), the human hepatic myofibroblast LX-2 
(19), quiescent human fibroblasts (hFB) kindly provided by V.H. Shah (Division of 
Gastroenterology and Hepatology, Mayo Clinic Rochester) and R.S. Bahn (Division of 
Endocrinology), the rat cholangiocarcinoma cell line BDEneu (20), BDEneu tumor 
associated myofibroblasts (rCAF)(21) and quiescent rat fibroblasts (rFB) were cultured in 
Dulbecco’s modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) under standard conditions. 
Cell lines were authenticated in June (HuCCT-1, MzChA-1, KMCH. KMBC) and July 
2011 (LX-2) by Genetica DNA Laboratories (Cincinnati, OH) using an AmpF/STR® 
Identifiler® kit and GeneMapper v3.2 software.  Three primary human 
cholangiocarcinoma associated myofibroblasts cell lines (hCAF) were isolated and 
cultured. These cell lines were obtained in full compliance and approval of the Mayo 
Institutional Review Board (IRB).  Briefly, liver cancer tissue was processed with the BD 
MediMachine (BD Biosciences, San Jose CA). Disaggregated cells were cultured in 
RPMI medium supplemented with 5% PLTMax (Mill Creek Life Sciences, Rochester, 
MN) (22). The hCAF cell lines were karyotyped to confirm a normal karyotype. 
Expansion media consisted of DMEM with 10% fetal bovine serum, 100 U/ml penicillin, 
100 g/ml streptomycin. 
Immunoprecipitation of Bcl-XL and associated BH3 only proteins. LX-2 cells 
were grown on 20 cm tissue culture dishes to subconfluency and treated with navitoclax 
(1 μM) for 24 hrs. Cells were subsequently lysed in cold CHAPS lysis buffer [1% 
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CHAPS, 150 mM NaCl, 20 mM HEPES, 1% Glycerol, 3% Thiodiglycol, 1 mM EGTA, 1 
mM sodium orthovanadate, 10 mM sodium pyrophosphate, 1 mM PMSF, 1x protease 
inhibitor mix, 100 mM sodium fluoride, 25 nM Microcystin]. Lysates were centrifuged 
for 15 min at 15000 x g to pellet cellular debris. Protein concentration was determined via 
Bradford assay. 400 µg of total protein were pre-cleared by incubation with 40 µl agarose 
A/G beads (Invitrogen, Camarillo, CA) for 1 hrs at 4°C. Bcl-XL (clone N-20, Santa Cruz 
Biotechnology (Santa Cruz, CA) and control rabbit IgG (BD Pharmingen, Franklin 
Lakes, NJ) crosslinked beads were prepared as previously described (23) 40µl of control 
IgG or Bcl-XL cross-linked beads were added to the precleared 400 µg of total lysate 
protein and incubated rotating over night at 4°C. The beads were then pelleted by 2 min 
centrifugation at 8000 x g, washed 4 times in CHAPS lysis buffer, resuspended in sample 
buffer [4 M urea, 2% SDS, 62.5 mM Tris-HCl (pH 6.8), 1 mM EDTA and 5% 2-
mercaptoethanol] and boiled for 20 min to release immunoprecipitated proteins. The 
samples were centrifuged 2 min at 8000 x g and the supernatant was subject to SDS-
PAGE and transfer to PVDF membrane as previously described. 
Bax activation by navitoclax. Cells were grown on glass slides and treated with 
navitoclax or vehicle. Slides were then washed with PBS fixed for 30 min with 4% 
paraformaldehyde and permeabilized with 0.01% CHAPS in PBS. After a further 
washing, slides were incubated with a conformation specific antibody against activated 
Bax 6A7 (1:100) over night at 4°C, washed and incubated with secondary antibody (goat-
anti mouse Alexa 488 1:1000) (24). 
Generation of stable transfectants. HEK 293T cells were transfected with 
pCMV-VSV-G (Addgene, Cambridge, MA), pCMV-dR8.2 dvpr (Addgene, Cambridge, 
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MA) and the lentiviral  shBax or shBak constructs (Open Biosystems, V2LHS_240441 
and V2LHS_94682), respectively, using Lipofectamine LTX reagent (Invitrogen, 
Camarillo, CA) to amplify the shBax or shBak containing lentivirus. Target LX-2 cells 
were grown to 50% confluency and infected with lentivirus containing medium from the 
HEK 293T cells. Medium was previously passed through a 0.45 µm pore filter and 
polybrene (Sigma Aldrich, St. Louis, MO) was then added to a final concentration of 8 
µg/ml. LX-2 cells were incubated with infectious medium for 3 hrs before medium was 
replaced with fresh non-infectious medium. Infection was again repeated 24 hrs after the 
initial exposure. Infected LX-2 cells were split into selection medium containing 10 
ug/ml puromycin. Cell lysates were prepared from shBax and shBak cells to confirm 
knockdown of Bax or Bak protein by Western blot. Stably transfected shMcl-1 KMCH 
clones were generated as previously described in detail (25).  LX-2 cells were stably 
transfected with an S-peptide tagged Mcl-1 construct as previously described for HuH-7 
cells (26).  The S-tag results in a slight increase in molecular weight for Mcl-1 which can 
readily be identified by immunoblot analysis to verify stable expression of the protein. 
 Syngeneic rodent model of intrahepatic cholangiocarcinoma. All animal 
experimentation described in this study was performed in accordance with and approved 
by the Institutional Animal Care and Use Committee. Syngeneic, in vivo cell 
transplantation was performed in adult Fischer 344 male rats (Harlan, Indianapolis, IN) 
with initial mean body weights ranging between 180 and 230 g, as we have previously 
described in detail (27). Buprenorphine (0.05 mg/kg SubQ) was used for postoperative 
analgesia. For apoptosis studies, navitoclax (5 mg/kg) or vehicle was given i.p. once daily 
for 2 consecutive days starting 7 d after tumor implantation. Twenty-four hours after 
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receiving the second treatment, the rats were euthanized and the livers were removed for 
analysis. For tumor size and metastasis analysis, navitoclax (5 mg/kg) or vehicle was 
given i.p. once daily for ten consecutive days starting 7 d after tumor implantation. 
Animals were sacrificed at day 18 and the livers were removed for analysis. Survival 
studies were performed as regulated by the Institutional Animal Care and Use Committee 
and animals were euthanized according to defined endpoints (weight loss > 25% of 
original body weight, disabilitating tumor mass, inability to reach food or water, 
moribund appearance).  
Statistical analysis.  Data represent at least three independent experiments using 
cells from a minimum of three separate isolations and are expressed as means ± SEM. 
Differences between groups were compared using two-tailed Student's t tests or χ2 tests. 
Survival data were analyzed and Kaplan-Meier graphs were generated using GraphPad 
Prism software 6 (GraphPad Software, La Jolla, CA). 
Other Materials and Methods.  Other materials and methods for PCR, cell death 
assays,  immunoblot analysis, mitochondrial membrane depolarization, Smac release and 
immunofluorescence are described in the Supplementary Materials and Methods. 
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RESULTS 
Navitoclax selectively induces myofibroblast apoptosis. CAF are characterized 
by the expression of α-smooth muscle actin (α-SMA) as a hallmark of the myofibroblast 
phenotype, and expression plus secretion of Ten C protein (4, 28).  We  confirmed  α-
SMA and Ten C and mRNA expression in hCAFs, human liver derived myofibroblastic 
LX-2 cell line and their shBAX and shBAK modified clones, as well as the absence of 
these markers in quiescent human fibroblasts (hFB) and human CCA cell lines 
(Supplemental. Fig. 1). Next we examined the potential, single-agent, pro-apoptotic 
effects of navitoclax on hCAF, LX-2, and hFB (Fig. 1A).  As assessed by both 
morphologic and biochemical criteria, navitoclax markedly induced apoptotic cell death 
in CAF and LX-2 cells, while quiescent fibroblasts were resistant to navitoclax 
cytotoxicity. To confirm that CAF were in fact undergoing caspase-dependent apoptosis, 
the pan-caspase inhibitor QVD was employed. QVD (5 mM) effectively reduced 
navitoclax induced apoptosis in CAF cells (<5% apoptotic cells after 48 hrs of 1 μM 
navitoclax treatment; data not shown). In contrast to the myofibroblasts, human CCA 
cells were relatively resistant to navitoclax-mediated cell death (Fig. 1B upper and lower 
panel), although the HuCCT-1 cell line displayed a moderate increase in caspase 3/7 
activity following exposure to navitoclax. The partial sensitivity of HuCCT-1 cells to 
navitoclax-induced apoptosis may be due to their enhanced Bax plus reduced Bcl-2 and 
Bcl-XL expression altering the complex balance of anti- and pro-apototic regulators 
(Supplemental Figure 2).  Finally, treatment of quiescent fibroblasts with TGF-β not only 
resulted in their activation, as observed by induction of α-SMA expression, but also 
sensitized these cells to navitoclax induced apoptosis (Supplemental Fig. 3). Taken 
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together, these data suggest navitoclax selectively induces apoptosis in CAF as compared 
to CCA cells. 
CAF do not express Mcl-1 and upregulate Bax. We next explored the potential 
mechanisms resulting in selective CAF sensitivity to navitoclax-mediated apoptosis.  We 
first profiled CAF for antiapoptotic multidomain Bcl-2 proteins (Bcl-2, Bcl-XL, and Mcl-
1), pro-apoptotic Bcl-2 proteins (Bax and Bak), and BH3-only proteins (Bad, Bim, Bid, 
Noxa, and PUMA) (Fig. 2A).  Expression of these proteins was quite variable between 
the different cell lines.  Interestingly, Mcl-1, a known resistance factor for navitoclax 
cytotoxicity (29), was not expressed by CAF or even quiescent fibroblasts, although it 
was expressed by CCA, as previously described (25) (Fig. 2B).   Bax was consistently 
up-regulated in the myofibroblasts as compared to quiescent fibroblasts (Fig. 2A), which 
is likely due to post-translational regulatory differences as Bax mRNA levels were 
similar between quiescent fibroblasts and the activated phenotype (data not shown). LX-2 
cells also displayed an increase of activated Bax compared to quiescent fibroblasts 
following navitoclax treatment (Fig. 2C). Finally, shRNA targeted knockdown of Bax but 
not Bak reduced navitoclax-induced cytotoxicity of myofibroblastic LX-2 cells (Fig. 2D).  
Although Mcl-1 has been previously identified as a resistance factor for navitoclax 
cytotoxicity (30), we further verified the effect of Mcl-1 on navitoclax sensitivity in our 
paradigms (Fig. 3). shRNA knockdown of Mcl-1 in KMCH cells sensitized the cancer 
cells to navitoclax-mediated apoptosis. Conversely, enforced expression of Mcl-1 in LX-
2 cells rendered these cells resistant to navitoclax-induced cell killing. Collectively, these 
observations suggest that the absence of Mcl-1 expression and the increase in Bax protein 
levels contribute to the sensitivity of CAFs to navitoclax-mediated apoptosis.  
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Liver myofibroblasts display mitochondrial priming for cell death.  
Navitoclax is incapable of directly inducing Bax activation (11, 31).  Moreover, quiescent 
fibroblasts were also resistant to navitoclax cell killing despite failure to express Mcl-1.  
To reconcile these observations, we postulated that CAF mitochondria were primed for 
cell death (32).  Mitochondrial priming refers to the empiric observation  that  activated 
or transformed cells have a reduced threshold  for BH3 peptide– or BH3 mimetic-induced 
mitochondrial release of apoptogenic factors such as Smac and cytochrome c  (33). For 
these studies we employed the LX-2 cells, given their ability to be easily transfected. 
Upon navitoclax treatment, we observed substantial Smac release from isolated cellular 
heavy membranes enriched in mitochondria (Fig. 4A) as well as into the cytoplasm of 
whole cells (Fig. 4B).  However, Smac release was not observed in shBax cells (Fig. 4C). 
Mitochondria from CCA cells did not display release of apoptogenic factors upon 
exposure to navitoclax (Fig. 4D). Finally, consistent with being primed for cell death, the 
LX-2 cells but not quiescent fibroblasts nor CCA cells underwent mitochondrial 
membrane depolarization following navitoclax treatment and this effect was abolished in 
shBax LX-2 cells (Fig. 4E).  To further examine mechanisms responsible for this 
observed priming, mitochondrial enriched heavy membrane fractions obtained from 
CCA, LX-2 and hCAF cells were profiled for activator BH3-only proteins (Bid, Bim and 
Puma), and Bax and Bak by immunoblot analysis (Fig. 5A).  Increased Bax, Bid and Bim 
were identified in the mitochondrial fraction of myofibroblasts but not CCA cells. In 
accordance with other studies of priming (30), navitoclax treatment of LX-2 cells 
decreased Bim binding to Bcl-XL as examined by immunoprecipitation studies (Fig. 5B). 
These observations support the concept that the activated state of CAF is associated with 
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translocation of Bax and BH3 only proteins to mitochondria. The presence of Bim 
association with Bcl-XL in the presence of Bax on mitochondria supports an embedded 
together model which primes the cells for cell death by navitoclax (13). 
Navitoclax reduces tumor burden and metastasis in vivo.  To ascertain whether 
the effects of navitoclax on CAF from CCA observed in vitro may be translated to an in 
vivo model, we employed a syngeneic, orthotopic rodent model of CCA (34). First, 
cytotoxicity assays for the employed BDEneu tumor cells and rCAF previously isolated 
from orthotopic rat tumors were performed analogous to the previous assays with human 
cells (Suppl. Fig. 4A and B). These studies demonstrated that rat CAF, similar to human 
CAF, are more sensitive to navitoclax than the corresponding cancer cells. To also 
confirm that the stromal composition in this animal model was comparable to human 
CCA (28), we performed immunofluorescence for CAF-derived Ten C, an extracellular 
matrix protein produced by myofibroblasts, and α-SMA, a marker of the activated 
myofibroblast phenotype (3). Cytokeratin 7 was employed to identify CCA cells and 
distinguish them from the CAF.  Indeed, the rodent CCA was associated with extensive 
tumor desmoplasia which strongly expressed CAF markers (Figure 6A).  We then asked, 
whether navitoclax treatment induces CAF cytotoxicity in vivo. Animals were treated 
with navitoclax for 48 h, 7 days after tumor implantation. TUNEL assays were then 
performed with dual labeling for α-SMA and cytokeratin 7 to assess for TUNEL 
positive/α-SMA (CAF) and/or TUNEL positive/CK7 cells (CCA cells).  The number of 
α-SMA positive cells which were TUNEL positive was increased compared to tumors 
from vehicle treated animals (Fig. 6B) and was greater than the TUNEL positive/CK7 
cells.  Consistent with this observation, there was also a net reduction in quantitative 
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immunofluorescence staining for the tumor stroma markers α-SMA and Ten C (Fig.  6C). 
This observation was also confirmed by quantitative analysis of α-SMA and Ten C 
mRNA expression in the tumor samples (Fig. 6D).  Finally, we examined the potential 
tumor suppressing effect of navitoclax treatment in this model. In vehicle and navitoclax 
treated rats, tumor weight and metastases were examined after 10 days of treatment, 
initiated 7 days after tumor implantation. Mean gross tumor wet weight (Fig. 7A) and 
mean tumor-liver weight ratio (Fig. 7B) were reduced in the navitoclax-treated animals. 
Peritoneal metastases were also reduced in this group (Fig. 7C).  The navitoclax 
treatment associated tumor suppressive effects also translated into an improved animal 
survival (Fig. 7D). The morphometric analysis revealed an altered tumor composition 
after 10 days of treatment, namely a reduction in the ratio of α-SMA and Ten C positive 
stroma to tumor area (Fig. 7E). Histologically the tumors appeared less desmoplastic with 
larger contiguous areas of tumor cells rather than isolated tumor glands typical for CCA 
(Fig. 7F). Finally, we were also able to demonstrate Bax activation and loss of 
mitochondrial Smac in CAF following navitoclax treatment for 48 hrs, thereby, 
suggesting the mechanisms of navitoclax-mediated CAF cytotoxicity in vivo parallels that 
observed in vitro (Supplemental Fig. 5). Taken together, these observations suggest 
navitoclax impairs tumor growth and metastasis by depleting the tumor stroma of CAF, 
thereby reducing the extent of growth supporting CCA tumor stroma. 
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DISCUSSION 
 
The results of this study provide new mechanistic insights regarding therapeutic 
targeting of CAF within the tumor microenvironment as an anticancer strategy. These 
data indicate that: (a) liver CAF: display sensitivity to single agent cell killing by the 
BH3 mimetic navitoclax; (b) the sensitivity of CAF to navitoclax is associated with 
enhanced Bax expression and mitochondrial priming for cell death; and (c) targeting CAF 
for cell death in the tumor microenvironment is therapeutic in a syngeneic rodent in vivo 
model of CCA. These findings are discussed in greater detail below. 
Navitoclax mimics the binding characteristics of the BH3-only protein Bad, and 
like Bad does not bind to the anti-apoptotic protein Mcl-1 (14); indeed, Mcl-1 expression 
is a well-documented resistance factor for navitoclax (29).  Given that CCA express Mcl-
1 (25), their resistance to navitoclax is not surprising.  However, resistance to navitoclax 
is unlikely to be mediated solely by a single Bcl-2 protein given the complexity of the 
interactions between pro- and anti-apoptotic members of this family.  For example, the 
HuCCT cells displayed partial sensitivity to navitoclax despite Mcl-1 expression, likely 
due to their increased Bax plus reduced Bcl-2 and Bcl-XL expression. Alternatively, lack 
of Mcl-1 phosphorylation at Ser-64 in these cells could potentially explain the 
insufficiency of Mcl-1 in preventing navitoclax cytotoxicity (35).   
The absence of Mcl-1 expression by CAF was unexpected, but, partially explains 
their sensitivity to navitoclax-mediated apoptosis.  The mechanism for silencing Mcl-1 
expression by CAF is beyond the scope of this study, given the complexity of Mcl-1 
regulation (36).   Because navitoclax cannot directly activate Bax or Bak, the absence of 
Mcl-1 expression is not sufficient to explain the sensitivity of CAF to navitoclax killing. 
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Indeed, quiescent fibroblasts were also resistant to navitoclax cytotoxicity despite their 
lacking of Mcl-1 expression.  These observations suggest CAF may also be primed for 
cell death. 
In one model, mitochondrial priming is considered to be a state in which the 
capacity of anti-apoptotic Bcl-2 proteins to sequester pro-apoptotic BH3 only proteins or 
bind Bax/Bak is almost completely exhausted (32).  In this situation minimal shifts of the 
Bcl-2 equilibrium can cause cells to rapidly enter apoptosis (37).  By binding to the anti-
apoptotic Bcl-2 proteins Bcl-2 and Bcl-XL, navitoclax displaces sequestered BH3 
proteins like Bim from these antiapoptotic proteins and enables them to activate Bax and 
Bak, inducing apoptosis (14). Indeed, we were able to demonstrate Bim displacement 
from Bcl-XL following navitoclax treatment in our current studies. In an alternative 
model, coined the “embedded together” model, anti-apoptotic proteins inhibit not only 
BH-3 only proteins, but also Bax or Bak all embedded within the outer mitochondrial 
membrane (13, 14) In this model, BH3 mimetics may alter binding between the various 
Bcl-2 binding polypeptides allowing Bax or Bak activation and MOMP.  Our data are 
perhaps most consistent with an embedded together model as we observed that Bim and 
Bax were already associated with mitochondria under basal conditions in myofibroblasts. 
Following navitoclax treatment, Bim was released from Bcl-XL suggesting the BH3 
mimetic altered the complex binding dynamics in the membrane in such a manner as to 
favor Bax activation and MOMP.   
In our in vivo studies, despite the more prominent cytotoxic effects on CAF as 
compared to CCA cells, navitoclax treatment was sufficient to markedly reduce tumor 
size. These observations support the concept that tumor stroma is crucial for tumor 
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development and even metastasis (38). Quantitative depletion of CAF from the stroma by 
navitoclax also reduced the expression of typical components of the tumor extracellular 
matrix, such as Ten C, a protein recently found to support cancer growth (6, 39, 40). 
Thus, therapeutic induction of CAF apoptosis can be coupled to a decrease in tumor 
promoting components of the extracellular matrix. The noticeable reduction in metastasis 
might be a result of this depletion particularly of Ten C from the microenvironment, 
which has just recently been described as important matrix component of the metastatic 
niche (6, 41). 
In this study we employed CCA as a model of a highly desmoplastic cancer 
containing abundant CAF and tumor-specific extracellular matrix (4). This cancer is 
similar to other desmoplastic cancers, such as prostate, breast and pancreatic cancer, 
where tumor stroma contributes to tumor development and progression (42, 43). Thus, 
the results of this study are not only germane to CCA, but may also provide information 
relevant to desmoplastic cancers in general (2, 44). While cancer therapy targeting the 
cancer cells becomes increasingly more individualized, reflecting the multitude of genetic 
and cell biological alterations an individual tumor may present, the stromal reaction of 
the organism appears more uniform across many different types of malignancies (45).  
This suggests the tumor stroma to be a viable and attractive target for combination anti-
cancer therapy. Our results further suggest that CAF priming to select pro-apoptotic 
therapies targeting this cell population represents a novel anticancer strategy. In this 
regard, navitoclax may be a clinically relevant therapeutic agent. 
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FIGURE LEGENDS  
Figure 1. Navitoclax induces apoptosis in  human CAF, but not CCA cells. 
Quiescent human fibroblast (hFB), human primary cancer associated fibroblast from 
three different CCA patients (hCAF 1, 2 and 3) and activated hepatic myofibroblasts 
(LX-2) were plated onto multiwell plates and grown to approximately 70% confluency. 
Cells were treated as indicated with increasing doses of navitoclax for 48 hrs. Cells were 
analyzed for apoptotic nuclear morphology by DAPI-staining and quantitation of 
apoptotic nuclei by fluorescence microscopy (panel A; mean ± SEM; n=3; ** p≤0.01). 
hFB, hCAF, LX2 as well as the human CCA cell lines HuCCT-1, Mz-ChA-1, KMCH 
and KMBC were treated with navitoclax (1μM) or vehicle for 48 hrs. Apoptosis was 
measured by DAPI-staining with quantitation of apoptotic nuclei by fluorescence 
microscopy (panel B, upper graph; mean ± SEM; n=3; ** p≤0.01) or fluorometric 
analysis of caspase 3/7 activity displayed as fold change compared to vehicle control 
(panel B, lower graph; mean ± SEM; n≥5; * p≤0.05). 
Figure 2. Activated hepatic myofibroblasts exhibit alterations in their Bcl-2 
protein profile and are sensitized to navitoclax by Bax. Whole cell lysates were 
prepared from quiescent hFB, hepatic myofibroblasts LX-2 and hCAF as well as 
quiescent rat fibroblasts (rFB), rat cancer associated fibroblasts (rCAF) and the malignant 
erbB-2/neu transformed rat cholangiocyte cell line (BDEneu) that is employed in the 
described in-vivo model of cholangiocarcinoma.  Cell lysates were subject to immunoblot 
analysis of Bcl-2 proteins. Except where indicated by white lines, all lanes were adjacent 
on the membranes; in some cases, additional lanes originally run between those shown 
are omitted for clarity (panels A and B). All full-length blots/gels are presented in 
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Supplementary Figure 6. hFB, LX-2 and hCAF cells were grown to approximately 50% 
confluency on glass chamber slides and treated with navitoclax (1μM) for the indicated 
time. Cells were then analyzed by fluorescence microscopy using a conformation-specific 
antibody (6A7) against activated Bax. Bax positive cells are plotted as percentage of all 
cells (panel C; mean ± SEM; n=4; ** p≤0.01). Wild-type LX-2 cells as well as stably 
transfected shBax and shBak LX-2 cells were treated with navitoclax (1µM, 24h) and 
apoptosis was assessed by DAPI staining and fluorescence microscopy (panel D upper 
graph; mean ± SEM; n=4; ** p≤0.01) as well as fluorometric measurement of caspase 3/7 
activity (panel D lower graph; mean ± SEM; n=6; ** p≤0.01) 
Figure 3. Knockdown of Mcl-1 in CCA cells induces navitoclax sensitivity 
while Mcl-1 overexpression in LX-2 cells confers resistance to navitoclax induced 
apoptosis. Mcl-1 was knocked down in the human CCA cell line KMCH by shRNA 
technique (Western blot for Mcl-1, see panel A inset) and cells were treated with 
navitoclax (1 μM) or vehicle for 48 hrs. Apoptosis was measured by DAPI-staining and 
fluorescence microscopy (panel A, upper graph; mean ± SEM; n=3; ** p≤0.01) or 
fluorometric analysis of caspase 3/7 activity displayed as fold change compared to 
vehicle control (panel A, lower graph; mean ± SEM; n≥5; ** p≤0.001). Mcl-1 was 
overexpressed in the activated hepatic myofibroblast LX-2 (Western blot for Mcl-1, see 
panel B inset) and cells were treated with navitoclax (1 µM or 5 µM) or vehicle for 48 
hrs. Apoptosis was assessed by DAPI-staining and measurement of caspase 3/7 activity 
as described above ( mean ± SEM; n=3; ** p≤0.01) 
Figure 4. Navitoclax selectively induces release of mitochondrial pro-
apoptotic factors in activated myofibroblasts. Heavy membranes enriched in 
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mitochondria were isolated from LX-2 cells and incubated with navitoclax (10 μM) or 
vehicle. Mitochondria were separated from supernatant by centrifugation and fractions 
were subject to immunoblot analysis to assay for Smac release from the mitochondria 
into the supernatant (panel A). LX-2 cells were treated with navitoclax (1 µM) and 
separated into cytoplasmic and mitochondria-containing fractions (pellet - loading 
control) by differential centrifugation after selective digitonin permeabilization. Fractions 
were analyzed for Smac and cytochrome C by immunoblot (panel B). Cytoplasmic and 
mitochondria-containing fractions (pellet) of shBax and shBak LX-2 cells and human 
CCA cell lines MzChA-1 and HuCCT-1 treated with navitoclax (1 μM) are shown in 
panels C and D, respectively.  Note in these short-term incubation studies, the pool of 
cytochrome C and/or Smac released was limited and did not significantly influence the 
amount of these proteins in the pellet.  hFB, LX-2, shBax LX-2 and Mz-ChA-1 CCA 
cells were treated with navitoclax or vehicle for 24 hrs. After tetramethylrhodamine 
methyl ester (TMRM, 100 nM) loading, cells were analyzed for mitochondrial 
depolarization and subsequent loss of fluorescence by flow cytometry. TMRM 
fluorescence (excitation wavelength 544 nM) intensity was measured in 50,000 cells 
(panel E).  
Figure 5. Activated myofibroblasts display increased localization of pro-
apoptotic BH3 only proteins to mitochondria and binding to anti-apoptotic Bcl-2 
proteins. Mitochondria from LX-2, hCAF and human CCA cells were isolated by 
nitrogen cavitation and subject to immunoblot analysis for pro-apoptotic Bcl-2 family 
proteins (panel A). Immunoprecipitation of Bcl-XL from cell lysates of LX-2 cells and 
subsequent immunoblot analysis for the pro-apoptotic BH3 only protein Bim is shown in 
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panel B. non-specific rabbit IgG was used as negative control during the 
immunoprecipitation (panel B).  
Figure 6.  Navitoclax depletes CAF from BDEneu tumors and reduces 
characteristic tumor stroma ECM. Immunofluorescence double stainings for α-SMA 
(red) and cytokeratin 7 (CK-7, green; panel A, upper image, 40x) as well as tenascin C 
(Ten C, green) and cytokeratin 7 (CK-7 red; panel A, lower image, 40x) were performed 
on representative sections of BDEneu tumors harvested 17 days after tumor cell 
implantation. Frozen sections of  BDEneu tumors from animals treated with two doses of 
vehicle or navitoclax (5 mg/kg) were stained for α-SMA or cytokeratin 7 and co-labeled 
with the TUNEL staining. The number of α-SMA/TUNEL and CK-7/TUNEL positive 
cells was assessed and plotted as percentage of all α-SMA or CK-7 positive cells, 
respectively (panel B; mean ± SEM; n=4; * p≤0.05). BDEneu tumors from animals 
treated with two doses of navitoclax  (5 mg/kg) were stained for  α-SMA, tenascin C and 
cytokeratin 7. Confocal microphotographs of representative tumor areas were analyzed 
by digital morphometry and α-SMA and tenascin C positive areas were expressed as 
percent of total tumor area (panel C; mean ± SEM; n=8; ** p≤0.001). α-SMA, Ten C and 
CK-7 mRNA expression was quantified by real-time PCR and normalized to 18S rRNA. 
Expression of  α-SMA and tenascin c mRNA was plotted as ratio to CK-7 to control for 
the quantity of tumor-stroma in the sample (panel D; mean ± SEM; n=7; * p≤0.05) 
Figure 7.  Navitoclax treatment reduces BDEneu tumor size and metastasis, 
improves survival and alters tumor composition. BDEneu tumors from animals treated 
with navitoclax (5 mg/kg) or vehicle for 10 days were carefully excised, remaining liver 
tissue was removed, then tumors were measured and weighted (panel A; mean ± SEM; 
on March 14, 2014. © 2012 American Association for Cancer Research.cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 5, 2012; DOI: 10.1158/0008-5472.CAN-12-2130 
Mertens et al -27-  
 
27 
 
n=8; * p≤0.05) and tumor-liver weight ratios were calculated (panel B; mean ± SEM; 
n=8; * p≤0.05). After removal of the liver, the peritoneal cavity was carefully examined 
for metastases (panel C; mean ± SEM; n=8; * p≤0.05). To assess effects of navitoclax on 
survival, animals were treated with navitoclax as described for 21 days and survival was 
documented (panel D; mean ± SEM; n=18; p≤0.05). Frozen tumor sections were stained 
for  α-SMA, tenascin C and cytokeratin 7. Digital morphometry was performed on 
confocal microphotographs and ratio of α-SMA and tenascin C positive stroma to tumor 
area was calculated (panel E; mean ± SEM; n=4; ** p≤0.01). Representative 
photomicrographs of hematoxylin-eosin stained tumor sections are shown in panel F. 
Characteristic tumor areas are outlined. 
 
 
  
 
on March 14, 2014. © 2012 American Association for Cancer Research.cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 5, 2012; DOI: 10.1158/0008-5472.CAN-12-2130 
50
Vehicle
A) B)
Figure 1
**
50
LX-2
hCAF 1
30
40
c
 
n
u
c
l
e
i
,
 
%
o
t
i
c
 
n
u
c
l
e
i
,
 
%
Navitoclax
20
30
40
**
10
20
A
p
o
p
t
o
t
i
c
A
p
o
p
t
o
0
10
**
**
hFB0
0 0.5 1 1.5 2
Navitoclax, µM
c
h
a
n
g
e
* *
6
3
/
7
 
a
c
t
i
v
i
t
y
,
 
f
o
l
d
 
*
*
*
2
4
C
a
s
p
a
s
e
3
0
Fibroblasts CCA cells
o
n
 M
arch 14, 2014. © 2012 Am
erican Association for Cancer Research.
ca
n
ce
rre
s.a
a
crjournals.org 
D
ow
nloaded from
 
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author M
anuscript Published O
nlineFirst on Decem
ber 5, 2012; DO
I: 10.1158/0008-5472.CAN-12-2130 
Bad
Actin
Bcl-2
Actin
Bax
Actin
A)
Figure 2
Bcl-XL
Actin
Bid
Actin
PUMA
NOXA
Actin
Actin
Bim
Actin
Bak
Actin
Bax
Actin
Mcl-1
B)
Actin
, %
40C) D)
45
**
**
e 
ce
lls
, %
A
po
pt
ot
ic
 n
uc
le
i,
10
20
30
25
30
35
40
**
**
B
ax
po
si
tiv
e
3
4
5
6
7 
ac
tiv
ity
, f
ol
d 
ov
er
 c
on
tr
ol
0
5
10
15
20
**
**
LX-2 WT shBak shBax
0
1
2
C
as
pa
se
3/
7
ch
an
ge
 o0
LX-2hFB hCAF 3
on March 14, 2014. © 2012 American Association for Cancer Research.cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 5, 2012; DOI: 10.1158/0008-5472.CAN-12-2130 
Figure 3
A)
60
B)
45 **Mcl-1
KMCH
shMcl-1wt
LX-2
wt MCL-1
1 2
40
50
n
u
c
l
e
i
,
 
%
**
n
u
c
l
e
i
,
%
Mcl-1
Actin
**
25
30
35
40Actin
10
20
30
A
p
o
p
t
o
t
i
c
 
n
A
p
o
p
t
o
t
i
c
n
*10
15
20
0
5
6
h
a
n
g
e
 
**
0
5
25
30
U
**
3
4
a
c
t
i
v
i
t
y
,
 
f
o
l
d
 
c
h
v
e
r
 
c
o
n
t
r
o
l
15
20
3
/
7
a
c
t
i
v
i
t
y
,
 
R
F
U
V h N V h N
0
1
2
C
a
s
p
a
s
e
3
/
7
 
o
v
0
5
10
C
a
s
p
a
s
e
3
e
KMCH wt
av
KMCH 
shMcl-1
e av
LX-2 wt LX-2 Mcl-1
clone 1
LX-2 Mcl-1
clone 2
o
n
 M
arch 14, 2014. © 2012 Am
erican Association for Cancer Research.
ca
n
ce
rre
s.a
a
crjournals.org 
D
ow
nloaded from
 
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author M
anuscript Published O
nlineFirst on Decem
ber 5, 2012; DO
I: 10.1158/0008-5472.CAN-12-2130 
Smac
A)
S pernatant
Figure 4
NavVeh
B)
Smac Cyt C
NavVehNavVeh
Hsp60
u
Pellet 
(loading control)
Cytoplasm
Pellet 
(loading control)
Smac Cyt C
Cytoplasm
Pellet 
(loading control)
Mz-ChA-1
Smac
NavVeh NavVeh NavVeh
LX-2
Cyt C
D)C)
Smac
Cytoplasm
LX-2
NavVeh
shBax
NavVeh NavVeh
shBak HuCCT-1
Smac
Pellet (loading control)
Supernatant
HSP60
Smac
Pellet (loading control)
E) hFB
ou
nt
ou
nt
LX-2
Veh Nav
Veh
600
400
600
400
C
el
l c
o
C
el
l c
o
Nav200
0
200
0
600600 10
1 102 103 104 101 102 103 104
C
el
l c
ou
nt
Mz-ChA-1
Nav Veh
C
el
l c
ou
nt
shBax LX-2
VehNav
400
200
400
200C
Fluorescence, RVU
C
Fluorescence, RVU
00
101 102 103 104 101 102 103 104
on March 14, 2014. © 2012 American Association for Cancer Research.cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 5, 2012; DOI: 10.1158/0008-5472.CAN-12-2130 
Figure 5
Bid
LX-2
NavVeh
A) B)
Bax
Puma
Bcl-XL
Bim
Bak
Bcl-XL
Bim
HSP60 Bcl-XL
Input
o
n
 M
arch 14, 2014. © 2012 Am
erican Association for Cancer Research.
ca
n
ce
rre
s.a
a
crjournals.org 
D
ow
nloaded from
 
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author M
anuscript Published O
nlineFirst on Decem
ber 5, 2012; DO
I: 10.1158/0008-5472.CAN-12-2130 
ls
, %
**50
60
A) B)
Figure 6
U
N
EL
 p
os
iti
ve
 c
el
l
**
40
30
20
50 µm
TU
α-SMA
positive
CK-7 positive
Veh Nav NavVeh
10
0
30
 %
50
%
C)
10
20
M
A
 p
os
iti
ve
 a
re
a,
**
30
n 
C
 p
os
iti
ve
 a
re
a,
 
**
0
α-S
Veh Navitoclax
0
10Te
n
Veh Navitoclax
30 1.0
D)
20
K
-7
 m
R
N
A
 ra
tio
0.5
K
-7
 m
R
N
A
 ra
tio
**
0
10
α-S
M
A
 / 
C
K
Veh Navitoclax
0
Te
n 
C
 / 
C
K
Veh Navitoclax
on March 14, 2014. © 2012 American Association for Cancer Research.cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 5, 2012; DOI: 10.1158/0008-5472.CAN-12-2130 
4 0.4
io
A) B) C)
Figure 7
50
s,
 %
n 
tu
m
or
 w
ei
gh
t, 
g
*
2
3
*
0 1
0.2
0.3
or
/li
ve
r w
ei
gh
t r
at
i
25
s 
w
ith
 m
et
as
ta
se
s
NavitoclaxVeh
M
ea
n
0
1
0
.
Veh Navitoclax
Tu
m
o
0
Veh Navitoclax
A
ni
m
al
D)
100
*
Vehicle
Navitoclax
ur
vi
va
l, 
%
50
p= 0.02
Days
Su
0 5 10 15 20
0
F)E)
15
20
25
ro
m
a 
ar
ea
, %
 
30
40
50
ro
m
a 
ar
ea
, %
 
Veh
0
5
10
α-S
M
A
 p
os
iti
ve
 s
tr
**
0
10
20
Te
n 
C
 p
os
iti
ve
 s
tr
**
100 µm
Navitoclax
Veh Navitoclaxα Veh Navitoclax
100 µm
on March 14, 2014. © 2012 American Association for Cancer Research.cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 5, 2012; DOI: 10.1158/0008-5472.CAN-12-2130 
